THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 94 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $61,299 | -21.7% | 7,103 | -6.0% | 0.00% | – |
| Q2 2023 | $78,246 | -9.3% | 7,560 | -4.9% | 0.00% | – |
| Q1 2023 | $86,279 | -2.3% | 7,952 | +1.1% | 0.00% | – |
| Q4 2022 | $88,279 | +5.1% | 7,868 | -5.0% | 0.00% | – |
| Q3 2022 | $84,000 | +12.0% | 8,280 | 0.0% | 0.00% | – |
| Q2 2022 | $75,000 | -8.5% | 8,280 | -3.1% | 0.00% | – |
| Q1 2022 | $82,000 | +30.2% | 8,548 | +49.5% | 0.00% | – |
| Q4 2021 | $63,000 | +50.0% | 5,718 | 0.0% | 0.00% | – |
| Q3 2021 | $42,000 | -49.4% | 5,718 | 0.0% | 0.00% | – |
| Q2 2021 | $83,000 | -29.1% | 5,718 | 0.0% | 0.00% | -100.0% |
| Q1 2021 | $117,000 | +14.7% | 5,718 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $102,000 | +20.0% | 5,718 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $85,000 | +16.4% | 5,718 | +63.6% | 0.00% | 0.0% |
| Q2 2020 | $73,000 | -9.9% | 3,495 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $81,000 | +17.4% | 3,495 | +30.5% | 0.00% | 0.0% |
| Q4 2019 | $69,000 | +32.7% | 2,679 | 0.0% | 0.00% | – |
| Q3 2019 | $52,000 | +18.2% | 2,679 | 0.0% | 0.00% | – |
| Q2 2019 | $44,000 | -27.9% | 2,679 | 0.0% | 0.00% | -100.0% |
| Q1 2019 | $61,000 | -11.6% | 2,679 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $69,000 | -21.6% | 2,679 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $88,000 | +44.3% | 2,679 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $61,000 | -6.2% | 2,679 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $65,000 | -13.3% | 2,679 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $75,000 | +31.6% | 2,679 | +61.6% | 0.00% | 0.0% |
| Q3 2017 | $57,000 | -13.6% | 1,658 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $66,000 | +8.2% | 1,658 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $61,000 | +15.1% | 1,658 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $53,000 | -43.6% | 1,658 | -36.4% | 0.00% | 0.0% |
| Q3 2016 | $94,000 | +74.1% | 2,607 | +9.9% | 0.00% | 0.0% |
| Q2 2016 | $54,000 | -85.2% | 2,372 | -79.2% | 0.00% | -90.9% |
| Q2 2014 | $364,000 | – | 11,428 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chescapmanager LLC | 1,134,718 | $23,160,000 | 2.47% |
| Baupost Group | 8,735,168 | $178,285,000 | 1.42% |
| Orbimed Advisors | 6,219,110 | $126,932,000 | 1.19% |
| CM Management, LLC | 50,000 | $1,021,000 | 0.76% |
| Tekla Capital Management LLC | 456,296 | $9,313,000 | 0.32% |
| Rock Springs Capital Management LP | 682,600 | $13,932,000 | 0.30% |
| Virtus ETF Advisers LLC | 32,871 | $671,000 | 0.28% |
| Cormorant Asset Management, LP | 550,000 | $11,226,000 | 0.25% |
| DAFNA Capital Management LLC | 41,165 | $840,000 | 0.20% |
| PEREGRINE CAPITAL MANAGEMENT LLC | 484,206 | $9,883,000 | 0.18% |